Evidence map›Paper›PMID 38497716›Full record

ArticleMicrobiology spectrum2024

Application of MALDI-TOF MS and machine learning for the detection of SARS-CoV-2 and non-SARS-CoV-2 respiratory infections.

Sergey Yegorov, Irina Kadyrova, Ilya Korshukov, Aidana Sultanbekova, Yevgeniya Kolesnikova, Valentina Barkhanskaya, Tatiana Bashirova, Yerzhan Zhunusov, Yevgeniya Li, Viktoriya Parakhina and 9 more

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 3 countries.

Sergey YegorovDepartment of Biochemistry and Biomedical Sciences, Michael G. DeGroote Institute for Infectious Disease Research, McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0002-7136-7921
Irina KadyrovaResearch Centre, Karaganda Medical University, Karaganda, Kazakhstan.ORCID 0000-0001-7173-3138
Ilya KorshukovResearch Centre, Karaganda Medical University, Karaganda, Kazakhstan.
Aidana SultanbekovaResearch Centre, Karaganda Medical University, Karaganda, Kazakhstan.ORCID 0000-0002-7136-7921
Yevgeniya KolesnikovaResearch Centre, Karaganda Medical University, Karaganda, Kazakhstan.
Valentina BarkhanskayaResearch Centre, Karaganda Medical University, Karaganda, Kazakhstan.
Tatiana BashirovaCity Centre for Primary Medical and Sanitary Care, Karaganda, Kazakhstan.
Yerzhan ZhunusovInfectious Disease Centre of the Karaganda Regional Clinical Hospital, Karaganda, Kazakhstan.
Yevgeniya LiInfectious Disease Centre of the Karaganda Regional Clinical Hospital, Karaganda, Kazakhstan.
Viktoriya ParakhinaInfectious Disease Centre of the Karaganda Regional Clinical Hospital, Karaganda, Kazakhstan.
Svetlana KolesnichenkoResearch Centre, Karaganda Medical University, Karaganda, Kazakhstan.
Yeldar BaikenSchool of Sciences and Humanities, Nazarbayev University, Astana, Kazakhstan.
Bakhyt MatkarimovNational Laboratory Astana, Centre for Life Sciences, Nazarbayev University, Astana, Kazakhstan.
Dmitriy VazenmillerResearch Centre, Karaganda Medical University, Karaganda, Kazakhstan.
Matthew S MillerDepartment of Biochemistry and Biomedical Sciences, Michael G. DeGroote Institute for Infectious Disease Research, McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada.
Gonzalo H HortelanoSchool of Sciences and Humanities, Nazarbayev University, Astana, Kazakhstan.
Anar TurmukhambetovaResearch Centre, Karaganda Medical University, Karaganda, Kazakhstan.
Antonella E ChescaFaculty of Medicine, Transilvania University, Brașov, Romania.
Dmitriy BabenkoResearch Centre, Karaganda Medical University, Karaganda, Kazakhstan.
Karaganda Medical University · KZNazarbayev University · KZMcMaster University Medical Centre · CATransylvania University of Brașov · RO

Funding

CIHR Postdoctoral fellowship (Competition #202210MFE)
6 · The paper itself

Abstract

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) could aid the diagnosis of acute respiratory infections (ARIs) owing to its affordability and high-throughput capacity. MALDI-TOF MS has been proposed for use on commonly available respiratory samples, without specialized sample preparation, making this technology especially attractive for implementation in low-resource regions. Here, we assessed the utility of MALDI-TOF MS in differentiating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vs non-COVID acute respiratory infections (NCARIs) in a clinical lab setting in Kazakhstan. Nasopharyngeal swabs were collected from inpatients and outpatients with respiratory symptoms and from asymptomatic controls (ACs) in 2020-2022. PCR was used to differentiate SARS-CoV-2+ and NCARI cases. MALDI-TOF MS spectra were obtained for a total of 252 samples (115 SARS-CoV-2+, 98 NCARIs, and 39 ACs) without specialized sample preparation. In our first sub-analysis, we followed a published protocol for peak preprocessing and machine learning (ML), trained on publicly available spectra from South American SARS-CoV-2+ and NCARI samples. In our second sub-analysis, we trained ML models on a peak intensity matrix representative of both South American (SA) and Kazakhstan (Kaz) samples. Applying the established MALDI-TOF MS pipeline "as is" resulted in a high detection rate for SARS-CoV-2+ samples (91.0%), but low accuracy for NCARIs (48.0%) and ACs (67.0%) by the top-performing random forest model. After re-training of the ML algorithms on the SA-Kaz peak intensity matrix, the accuracy of detection by the top-performing support vector machine with radial basis function kernel model was at 88.0%, 95.0%, and 78% for the Kazakhstan SARS-CoV-2+, NCARI, and AC subjects, respectively, with a SARS-CoV-2 vs rest receiver operating characteristic area under the curve of 0.983 [0.958, 0.987]; a high differentiation accuracy was maintained for the South American SARS-CoV-2 and NCARIs. MALDI-TOF MS/ML is a feasible approach for the differentiation of ARI without specialized sample preparation. The implementation of MALDI-TOF MS/ML in a real clinical lab setting will necessitate continuous optimization to keep up with the rapidly evolving landscape of ARI.IMPORTANCEIn this proof-of-concept study, the authors used matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and machine learning (ML) to identify and distinguish acute respiratory infections (ARI) caused by SARS-CoV-2 versus other pathogens in low-resource clinical settings, without the need for specialized sample preparation. The ML models were trained on a varied collection of MALDI-TOF MS spectra from studies conducted in Kazakhstan and South America. Initially, the MALDI-TOF MS/ML pipeline, trained exclusively on South American samples, exhibited diminished effectiveness in recognizing non-SARS-CoV-2 infections from Kazakhstan. Incorporation of spectral signatures from Kazakhstan substantially increased the accuracy of detection. These results underscore the potential of employing MALDI-TOF MS/ML in resource-constrained settings to augment current approaches for detecting and differentiating ARI.

Indexed as

COVID-19Machine LearningRespiratory Tract InfectionsSARS-CoV-2Spectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAdultFemaleHumansKazakhstanMaleMiddle AgedNasopharynxSensitivity and Specificityacute respiratory infectionCOVID-19machine learningMALDI-TOF MSSARS-CoV-2

Identifiers

PMID38497716
PMCPMC11064577
OpenAlexW4392927797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.